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Abstract
Background: Low vitamin E levels are often found in HIV-1 infection, and studies have suggested
that higher levels may decrease the risk of disease progression. However, vitamin E
supplementation has also been reported to increase CCR5 expression, which could increase HIV-
1 replication. We hypothesized that vitamin E levels at HIV-1 acquisition may influence disease
progression.
Methods: Vitamin E status was measured in stored samples from the last pre-infection visit for 67
Kenyan women with reliably estimated dates of HIV-1 acquisition. Regression analyses were used
to estimate associations between pre-infection vitamin E and plasma viral load, time to CD4 count
<200 cells/µL, and mortality.
Results: After controlling for potential confounding factors, each 1 mg/L increase in pre-infection
vitamin E was associated with 0.08 log10 copies/mL (95% CI -0.01 to +0.17) higher set point viral
load and 1.58-fold higher risk of mortality (95% CI 1.15–2.16). The association between higher pre-
infection vitamin E and mortality persisted after adjustment for set point viral load (HR 1.55, 95%
CI 1.13–2.13).
Conclusion:  Higher pre-infection vitamin E levels were associated with increased mortality.
Further research is needed to elucidate the role vitamin E plays in HIV-1 pathogenesis.
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Background
Vitamin E plays a complex role in maintaining immune
function. Low levels of this micronutrient have been
found in HIV-1-infected individuals with both asympto-
matic and advanced disease [1,2]. In vitro, vitamin E has
been reported to inhibit HIV-1 transcription and to sup-
press the activation of virus in latently infected cells [3,4].
Generally, a protective effect in HIV-1 infected persons
has been assumed [5]. However, the effect of vitamin E on
HIV-1 disease progression has not been well character-
ized, and its overall role remains unclear. Moreover,
recent evidence suggests that vitamin E supplementation
may increase CCR5 expression, which in turn could
increase HIV-1 replication [6].
In prospective studies of HIV-1-infected people, higher
vitamin E levels and higher intake have been associated
with a lower risk of progression to AIDS [7,8]. However,
vitamin E levels can decrease as HIV-1 infection
progresses, and deficiencies found late in disease may
result from advanced illness [9]. Most studies have been
limited in their ability to determine the temporal
sequence of HIV-1 acquisition and development of defi-
ciencies. In addition, studies showing an advantage to
high levels of vitamin E may have been confounded by
factors (e.g., socioeconomic status) associated both with
better nutritional intake or supplement use and with bet-
ter HIV-1 disease outcomes.
Prospective studies of individuals who have been fol-
lowed since prior to HIV-1 seroconversion provide a
unique opportunity to study the effect of nutritional sta-
tus before acquisition of the virus on the progression of
HIV-1 disease. The Mombasa cohort was established to
evaluate risk factors for HIV-1 acquisition and disease pro-
gression in a population of female sex workers. The pur-
pose of this analysis of prospectively collected data from
the cohort was to test the hypothesis that pre-infection
vitamin E levels would be associated with HIV-1 disease
outcomes.
Methods
Beginning in February 1993, HIV-1-seronegative female
sex workers attending a municipal clinic in Mombasa,
Kenya were invited to participate in a prospective cohort
study of risk factors for HIV-1 acquisition. Women were
interviewed at study enrollment and at monthly intervals
thereafter. A physical examination performed at each visit
included specimen collection for diagnosis of sexually
transmitted diseases. In addition, a blood sample was
obtained for HIV-1 serologic testing. Women who sero-
converted to HIV-1 during follow-up were asked to con-
tinue monthly clinic visits, and quarterly CD4 counts were
obtained beginning in April 1998.
Services provided to study participants included HIV-1
counseling and testing, diagnosis and treatment of sexu-
ally transmitted diseases, and general outpatient care. For
HIV-1 infected women, care included trimethoprim-sul-
famethoxazole prophylaxis and treatment of opportunis-
tic infections. During the study period, no women
reported receiving antiretroviral therapy, which had lim-
ited availability in Kenya before 2004. Starting in March
2004, free antiretroviral therapy was provided to cohort
participants according to WHO and Kenyan Ministry of
Health Guidelines.
Participants who missed two consecutive clinic appoint-
ments were traced by study staff. For women who died,
information on the date of death was collected from fam-
ily, employers, or colleagues during tracing visits. From
1993 to 2000, we obtained verbal informed consent after
participants either read or listened to a study nurse read a
standardized consent document. Beginning in 2000, we
implemented written consent for all new and continuing
participants. This research was approved by the University
of Washington, University of Nairobi, and Fred Hutchin-
son Cancer Research Center ethical review committees.
HIV-1 serologic testing was performed by an ELISA
(Detect HIV, BioChem ImmunoSystems, Montreal, QC,
Canada) and positive results confirmed by a second ELISA
(Recombingen, Cambridge BioTechnology Ltd., Worces-
ter, MA, USA). For women who seroconverted during fol-
low-up, plasma samples from the two clinic visits before
seroconversion were tested for HIV-1 RNA, using the Gen-
Probe HIV-1 viral load assay [10,11]. A level of ≥100 cop-
ies/mL was used to define detection of virus in plasma.
When RNA was detected, the date of infection was esti-
mated at 17 days before the first RNA-positive sample. For
women who had no plasma viremia detected before HIV-
1 seroconversion, the date of infection was estimated at
the midpoint between the last seronegative and the first
seropositive visit. Women with >1 year between these two
visits were excluded unless a positive HIV-1 RNA level was
present before seroconversion, because the date of infec-
tion could not be estimated with sufficient precision.
Absolute CD4 counts were measured by one of two meth-
ods (Cytosphere, Beckman Coulter Corporation, Miami,
FL, USA, or Zymmune, Bartels, Inc., Issaquah, WA, USA),
which have been demonstrated to generate comparable
results [12]. The first plasma viral load between 4 and 24
months after HIV-1 infection was taken to be the set point
viral load.
Vitamin E levels in plasma were assessed by high perform-
ance liquid chromatography [13]. For 7 participants, a
serum sample was the only pre-infection sample availa-
ble. Because values measured in serum and plasma areBMC Infectious Diseases 2007, 7:63 http://www.biomedcentral.com/1471-2334/7/63
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comparable within the normal range [14], stored serum
or plasma samples were used for assessment of vitamin E.
SPSS (version 12.0; SPSS Inc., Chicago, IL, USA) was used
for data analysis. The viral load was set at 50 copies/mL for
2 samples with an HIV-1 RNA set point <100 copies/mL.
Linear regression was used to estimate associations
between pre-infection vitamin E level and set point viral
load. Cox proportional hazards regression analysis was
performed to evaluate the association between pre-infec-
tion vitamin E and time to CD4 count <200 cells/µL or
death. Follow-up was censored at death or the last clinic
visit. Multivariate models were used to control for poten-
tial confounding factors of the association between vita-
min E status and HIV-1 disease progression, including
hormonal contraceptive use and genital ulcer disease at
the time of infection [11].
Results
Between February 1993 and August 2001, 228 women
seroconverted for HIV-1. Data on the follow-up of these
women through March 2004 were included in this analy-
sis. Sixty-seven (29%) were excluded because the date of
infection could not be estimated with sufficient precision.
Ninety-four women (42%) did not have blood samples
available from the time points of interest (i.e., pre-infec-
tion and set point samples). The remaining 67 (29%)
were eligible for analysis in this study, and vitamin E was
assessed at the last pre-seroconversion visit at which no
HIV-1 RNA was detected.
Pre-infection samples were collected a median of 30 days
(IQR, 16 – 59) before HIV-1 infection. The median pre-
infection vitamin E level was in the low-normal range (7.5
mg/L; IQR, 5.2 – 9.5) and the prevalence of vitamin E defi-
ciency (<5 mg/L) was 21%. Baseline characteristics for the
67 women included are summarized in Table 1. Women
included in the analysis had a lower number of sex part-
ners and sexual frequency in the 6 months preceding HIV-
1 infection, but did not differ significantly from the 161
seroconverters excluded from this study for any of the
other characteristics presented in Table 1.
The 67 women were followed for a median of 68 months
(IQR, 45 – 85). Set point samples were collected a median
of 199 days (IQR, 154 – 267) after HIV-1 infection. The
median set point viral load was 4.7 log10 copies/mL (IQR,
3.9 – 5.2). CD4 lymphocyte counts were available for 55
women (82%). Nineteen women (28%) progressed to a
CD4 count <200 cells/µL, and twelve women (18%) died
during follow-up: 1 with pneumonia, 1 with fever, 1 with
hematemesis and abdominal distention, and 9 of
unknown causes. Each 1-unit increase in log10 set point
viral load was associated with a hazard ratio of 1.31 (95%
CI, 0.83–2.07, p = 0.248) for the risk for progression to a
CD4 count <200 cells/µl and 1.66 (95% CI, 0.80–3.45, p
= 0.176) for the risk of death.
After adjustment for potential confounding factors, each 1
mg/L increase in pre-infection vitamin E level was associ-
ated with a 0.08 log10 copies/mL higher set point viral
load (Table 2). No significant association was found
between pre-infection vitamin E and time to CD4 count
<200 cells/µL. Higher pre-infection vitamin E levels were
associated with a 1.16-fold higher mortality risk. After
adjustment, this association was strengthened to a 1.58-
fold increase in mortality risk. Higher mortality persisted
after further adjustment for set point viral load (adjusted
hazard ratio 1.55, 95% CI 1.13 – 2.13, p = 0.006).
Table 2: Association between pre-infection vitamin E status and measures of HIV-1 disease progression
Outcomes β (95% CI)
or HR (95% CI)
P Adjusted* β (95% CI)
or HR (95%CI)
P
Set point viral load (log10 copies/ml) +.09 (+.01, +.17) 0.038 +.08 (-.01, +.17) 0.066
CD4 count <200 cells/µL 0.99 (0.86, 1.13) 0.85 1.02 (0.88, 1.18) 0.79
Mortality 1.16 (1.02, 1.33) 0.024 1.58 (1.15, 2.16) 0.004
β, mean change in outcome for each 1 mg/L increase in vitamin E (linear regression); CI, confidence interval; HR, hazard ratio (Cox proportional 
hazards regression).
* Adjusted for age at infection, education, parity, hormonal contraception at infection, GUD at infection [11].
Table 1: Characteristics of 67 Kenyan women at the time of HIV-
1 infection
Characteristic N (%) or Median (IQR)
Age, years 28 (25 – 35)
Education, years 8 (7 – 10)
Live births 1 (1 – 2)
Sex partners per week* 1.0 (0.7 – 1.0)
Sex frequency per week* 1.3 (1.0 – 2.0)
Frequency of condom use (%)* 83 (40 – 100)
Use of hormonal contraceptive method
Oral contraceptive pill 15 (22.4%)
DMPA† 23 (34.3%)
Norplant 1 (1.5%)
None reported 28 (41.8%)
Genital ulcer disease 3 (4.5%)
Time in cohort before infection, months 9 (3 – 21)
* Average values per week for each woman, for the 6 months 
preceding HIV-1 infection.
† Depot medroxyprogesterone acetateBMC Infectious Diseases 2007, 7:63 http://www.biomedcentral.com/1471-2334/7/63
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Discussion
In this study of women with well-defined dates of HIV-1
infection, vitamin E levels before HIV-1 infection were
associated with higher mortality. For each 1 mg/L increase
in pre-infection vitamin E, there was an approximately
60% higher relative risk of death. An association between
higher vitamin E levels and higher set point viral load was
of borderline significance. However, the higher mortality
risk persisted after adjustment for set point viral load, sug-
gesting that the association between pre-infection vitamin
E and mortality may be independent of its effect on the
plasma viral load at set point.
A higher prevalence of vitamin E deficiency in HIV-1-
infected individuals than in uninfected controls was
reported soon after HIV-1 testing became available [1].
Few prospective studies of nutritional status in HIV-1-
infected persons have specifically analyzed vitamin E lev-
els. In a Baltimore cohort, HIV-1-seropositive men in the
highest quartile of vitamin E levels at enrollment showed
a lower risk of progression to AIDS compared with the rest
of the cohort (HR 0.67, 95% CI 0.45–0.98), although
there was no apparent relationship between low vitamin
E levels and risk of progression to AIDS or mortality [7].
In a Miami cohort of HIV-1-seropositive women, vitamin
E status was not significantly associated with survival [15].
Thus, evidence for a possible association between vitamin
E levels and HIV-1 disease progression is not conclusive.
The mechanism by which higher vitamin E could acceler-
ate HIV-1 disease progression is unknown, but vitamin E
has been found to influence the production of RANTES,
an important antiviral chemokine. In a small supplemen-
tation study, 500 mg of alpha-tocopherol (the most
potent of the tocopherols with vitamin E activity) given
once daily for 2 months reduced RANTES production and
increased the expression of CCR5 on the surface of CD4+
T cells of HIV-1 infected persons [6]. Endogenous produc-
tion of antiviral factors like RANTES may significantly
affect HIV-1 replication and the pace of disease progres-
sion [16]. Increased CCR5 expression and decreased
RANTES levels would be expected to increase HIV-1 repli-
cation.
There are three important strengths of this study. First,
because the women were followed prior to seroconver-
sion, vitamin E levels could be tested on samples collected
before HIV-1 acquisition, when low vitamin E status
could not be a result of disease progression. Second, the
frequent follow-up allowed measurement of pre-infection
vitamin E status within 2 months of the estimated time of
infection. Third, outcomes accrued over several years, and
there was active tracing of participants lost to follow-up.
There were some limitations to this study. First, CD4 cell
counts were not available before April 1998. Thus, for
some women, the first CD4 measurement was <200 cells/
µL, decreasing our ability to measure progression to this
endpoint with precision. Second, a reliable estimate of the
time of infection and the required samples were available
for only a minority of seroconverters in the Mombasa
cohort (29%). Although it reduced the sample size, this
limitation did not compromise the internal validity of the
study, and we still found significant associations between
vitamin E status and both set point viral load and HIV-1
disease progression. Third, the cause of death was
unknown for most of the women included, and not all
deaths can be attributed to HIV-1 disease despite rigorous
efforts to trace women. However, survival among HIV-1-
seroconverters in our cohort prior to antiretroviral therapy
is similar to that of other seroconverter cohorts in which
HIV-1 has been causally related to death among those
infected [17,18]. Fourth, most of the women in our cohort
are infected with HIV-1 subtype A, which has been associ-
ated with a slower rate of disease progression, compared
to other subtypes [19]; this may have influenced the asso-
ciations we detected.
Finally, no data were collected on vitamin E intake for
these women. Vitamin E status is influenced by a number
of factors (e.g., dietary fat intake, body mass index, smok-
ing, seasonal variation in food availability), and the vita-
min E levels found in this study were similar to those
reported previously in studies of African females [20,21].
This study was not designed to test the hypothesis that
higher vitamin E intake or vitamin E supplementation
would influence HIV-1 disease progression.
Conclusion
In conclusion, the findings of this study provide evidence
that higher vitamin E levels may have undesirable effects
in HIV-1 infection. Further research is needed to deter-
mine whether these findings can be replicated in other
cohorts and to better understand the mechanisms by
which vitamin E may influence HIV-1 replication and dis-
ease progression.
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